Personalized cancer vaccine shows promise in early trial

NCT ID NCT03289962

Completed Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 01, 2026 · Last updated Jun 12, 2026 · Updated 2 times

Summary

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. The goal was to find the best dose and check for side effects, not to cure the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Akademiska sjukhuset, Onkologkliniken

Uppsala, 75185, Sweden
Antoni van Leeuwenhoek Ziekenhuis

Amsterdam, 1066 CX, Netherlands
Barts Health NHS Trust - St Bartholomew's Hospital

London, EC1M 6BQ, United Kingdom
CHU de Liège (Sart Tilman)

Liège, 4000, Belgium
Clinica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain
Columbia University Medical Center

New York, New York, 10032, United States
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

Las Vegas, Nevada, 89169, United States
Dana Farber Can Ins

Boston, Massachusetts, 02215, United States
Fachklinik für Lungenerkrankungen

Immenhausen, 34376, Germany
HonorHealth Research Institute ? Bisgrove

Scottsdale, Arizona, 85258, United States
Karolinska Universitetssjukhuset, Solna

Stockholm, 751 85, Sweden
Massachusetts General Hospital.

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Nationales Centrum für Tumorerkrankungen Heidelberg (NCT)

Heidelberg, 69120, Germany
Princess Margaret Cancer Center

Toronto, Ontario, M5G 2M9, Canada
Providence Oncology and Hematology Care Eastside

Portland, Oregon, 97213, United States
Sarah Cannon Res Inst

Nashville, Tennessee, 37203, United States
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Southampton General Hospital

Southampton, SO16 6YD, United Kingdom
Stanford Cancer Center

Stanford, California, 94305, United States
The Los Angeles Clinic

Los Angeles, California, 90025, United States
The Ottawa Hospital Cancer Centre

Ottawa, Ontario, K1H 8L6, Canada
The Royal Marsden Hospital

Sutton, SM2 5PT, United Kingdom
UCSF Comprehensive Cancer Ctr

San Francisco, California, 94143, United States
UZ Gent

Ghent, 9000, Belgium
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

Mainz, 55101, Germany
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands
University of Colorado

Aurora, Colorado, 80045-2517, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
Universitätsklinikum Essen

Essen, 45122, Germany
Vall d?Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, 08035, Spain
Yale University Cancer Center, Smilow Cancer Hospital

New Haven, Connecticut, 06511, United States
ZAS Sint Augustinus Wilrijk

Wilrijk, 2610, Belgium

Conditions

Explore the condition pages connected to this study.

BLADDER CANCER COLORECTAL CANCER HEAD AND NECK CANCER MELANOMA NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER OTHER SOLID CANCERS RENAL CANCER TRIPLE NEGATIVE BREAST CANCER